Le Lézard
Classified in: Science and technology, Business
Subject: DIV

Genpact Limited Board Declares Quarterly Cash Dividend


NEW YORK, May 2, 2024 /PRNewswire/ -- Genpact Limited (NYSE: G), a global professional services and solutions firm delivering outcomes that shape the future, today announced that its board of directors has declared a cash dividend of $0.1525 per common share for the second quarter of 2024. The dividend is payable on June 26, 2024 to shareholders of record as of the close of business on June 10, 2024. The declaration of any future dividends will be at the discretion of the board of directors.

About Genpact

Genpact (NYSE: G) is a global professional services and solutions firm delivering outcomes that shape the future. Our 125,000+ people across 30+ countries are driven by our innate curiosity, entrepreneurial agility, and desire to create lasting value for clients. Powered by our purpose ? the relentless pursuit of a world that works better for people ? we serve and transform leading enterprises, including the Fortune Global 500, with our deep business and industry knowledge, digital operations services, and expertise in data, technology, and AI. 

Get to know us at genpact.com and on LinkedInXYouTube, and Facebook.

Safe Harbor

Statements in this press release regarding Genpact's intention to pay dividends on its common shares from time to time are forward-looking statements. There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements. These include, among others, Genpact's cash flows from operations, macroeconomic uncertainty and general economic conditions, any deterioration in the global economic environment and its impact on our clients, technological innovation, including AI technology and future uses of generative AI and large language models, and our ability to invest in new technologies and adapt to industry developments at sufficient speed and scale, our ability to develop and successfully execute our business strategies, our ability to effectively price our services and maintain pricing and employee utilization rates, general inflationary pressures and our ability to share increased costs with our clients, wage increases in locations in which we have operations, our ability to attract and retain skilled professionals, the economic and other impacts of geopolitical conflicts, as well as any potential expansion or escalation of these conflicts or resulting economic disruption beyond the current scope, and other factors identified in our most recent Annual Report on Form 10-K and other reports filed with the SEC. Genpact undertakes no obligation to update any forward-looking statements that may be made from time to time by or on behalf of Genpact.

Contacts:

Investors       

Tiffany Horvath


+1 (614) 625-6485


[email protected]



Media

Siya Belliappa

+1 (718) 561-9843

[email protected]

 

SOURCE Genpact


These press releases may also interest you

at 07:05
Battery Ventures, a global, technology-focused investment firm, announced it has closed its take-private acquisition of field-service workflow company TrueContext, formerly known as ProntoForms. The Canadian software company was officially delisted...

at 07:05
Marti Technologies, Inc. ("Marti" or the "Company") , Türkiye's leading mobility super app, today announced that it has appointed Oguz Erkan as its new Chief Financial Officer ("CFO"), effective May 17, 2024. Oguz Erkan replaces the Company's former...

at 07:05
Precision BioSciences, Inc. , an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today...

at 07:05
Verdantis, a pioneering leader in AI-powered data solutions, proudly announces the appointment of Kumar Gaurav Gupta as its new Chief Executive Officer (CEO). Taking on the role of CEO he shoulders the responsibility of propelling growth, with a...

at 07:01
The enterprise software market is one of the fastest-growing segments within the IT industry. A Statista report shows that it consistently experiences over 10% year-on-year growth...

at 07:00
XORTX Therapeutics Inc. ("XORTX" or the "Company") , a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that further to its press releases of March 11 and April 30,...



News published on and distributed by: